Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
Status:
Not yet recruiting
Trial end date:
2029-07-31
Target enrollment:
Participant gender:
Summary
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in
comparison to placebo after 2 years in patients with compensated cirrhosis.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborators:
Columbia University Duke University LAC+USC Medical Center Mayo Clinic National Cancer Institute (NCI) National Institute on Alcohol Abuse and Alcoholism (NIAAA) The Cleveland Clinic University of California, San Diego University of California, San Francisco University of Miami University of Michigan University of Southern California Virginia Commonwealth University Weill Medical College of Cornell University